Last reviewed · How we verify

GI148512 — Competitive Intelligence Brief

GI148512 (GI148512) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE4 inhibitor. Area: Respiratory / Immunology.

phase 3 PDE4 inhibitor PDE4 Respiratory / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

GI148512 (GI148512) — GlaxoSmithKline. GI148512 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GI148512 TARGET GI148512 GlaxoSmithKline phase 3 PDE4 inhibitor PDE4
Otezla APREMILAST Amgen marketed Phosphodiesterase 4 Inhibitor [EPC] PDE4 2014-01-01
Apremilast (CC-10004) Apremilast (CC-10004) Virginia Clinical Research, Inc. marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Crisaborole Vehicle Crisaborole Vehicle Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
Crisaborole ointment, 2% Crisaborole ointment, 2% Pfizer marketed Phosphodiesterase 4 (PDE4) inhibitor PDE4
PMF104 PMF104 Alfasigma S.p.A. phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4
LEO 90100 LEO 90100 LEO Pharma phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE4 inhibitor class)

  1. GlaxoSmithKline · 7 drugs in this class
  2. Almirall, S.A. · 4 drugs in this class
  3. Pfizer · 3 drugs in this class
  4. Dr. Reddy's Laboratories Limited · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Handok Inc. · 1 drug in this class
  7. R-Pharm · 1 drug in this class
  8. Advenchen Pharmaceuticals, LLC. · 1 drug in this class
  9. Shaanxi Micot Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GI148512 — Competitive Intelligence Brief. https://druglandscape.com/ci/gi148512. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: